RxDoctor Payments Data

Kristin Delisi

Adult Health · Pittsburgh, PANPI 1851430714

Payments from drug & device makers

$6,729in general payments, 2019–2025

Across 33 payments — averaging $203.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$5K
  • Novo Nordisk$676
  • Abbott$141
  • Tandem Diabetes Care, Inc.$129
  • Inspire Medical Systems, Inc.$119
  • Dexcom, Inc.$117
  • plus $280 from 3 others

What the payments were for

  • Consulting fees$3,16447%
  • Travel & lodging$1,00815%
  • Food & beverage$2,55638%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,729 in reported general payments places this provider in the 90th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,728
Medicare patients
77
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$58,604
JardianceEmpagliflozin44$53,290
MounjaroTirzepatide34$45,792
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$41,003
TrulicityDulaglutide28$27,718
TradjentaLinagliptin20$19,061
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,243
Humalog Kwikpen U-100Insulin Lispro19$4,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,410
Novolog FlexpenInsulin Aspart14$4,315
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$2,473
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic12$819
Metformin Hcl ErMetformin Hcl24$304
Levothyroxine Sodium29$292
Metformin Hcl12$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$106$72,35164 claims
Novo NordiskOzempic$676$58,60455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →